Clinical Trial Detail

NCT ID NCT02991651
Title Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Io Therapeutics
Indications

lung non-small cell carcinoma

Therapies

Erlotinib + IRX4204

Age Groups: senior adult

No variant requirements are available.